OccamzRazor is developing curative treatments for complex brain-aging diseases, including Parkinson's disease, by combining machine learning and data-driven hypothesis generation. The company builds an AI-enabled discovery platform that uses graph machine learning (RazorBrain), graph prediction (RazorLink) and natural language processing (RazorPanorama) to generate testable, data-driven hypotheses. Led by CEO Katharina Sophia Volz, OccamzRazor is headquartered at Johnson & Johnson's J-LABS innovation hub in New York City. The company raised $6.1M in a financing round led by Jeff Dean with participation from Lauder Partners, re.Mind Capital and Valor Equity Partners. OccamzRazor intends to use the funds to launch its AI-enabled discovery pipeline and advance preclinical development in Parkinson's disease.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2022